Call for comments by Friday, 8 June 2018 - closed
The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, with support from the Welcome Trust and in collaboration with the WHO, has been tasked with facilitating the collaborative development of a "Lassa fever R&D Roadmap".
The roadmap prioritizes the development of countermeasures (diagnostics, therapeutics and vaccines) that are most needed by Lassa fever -affected countries and is the result of extensive consultations with the Lassa R&D roadmap taskforce, leading national and international experts and other key stakeholders.
Final roadmap to be published soon
Please provide comments on the draft Lassa R&D roadmap using the comment form posted on this webpage. You may provide feedback either for the entire roadmap document or only parts of it. Comments may be publicly disclosed at a later stage of the review process; submission of comments will be considered as permission to publicly disclose the comment form. Comments may be submitted by individuals or organizations, and can be submitted in English or French.
Please send your comments to LassaRDRoadmap@who.int with the subject line “Comments on draft Lassa R&D roadmap” by no later than Friday, 8 June 2018. Input received from this public consultation will contribute to the further development and refinement of the roadmap.
Please note that the sections on milestones, implementation strategies and schedule, and critical path analysis will be available at a later stage and are not currently incorporated in this draft of the roadmap document